93.02
2.95 (3.27%)
| Previous Close | 90.07 |
| Open | 92.06 |
| Volume | 605,729 |
| Avg. Volume (3M) | 931,670 |
| Market Cap | 5,261,729,792 |
| Price / Sales | 12.39 |
| Price / Book | 6.64 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 |
| Profit Margin | -38.17% |
| Operating Margin (TTM) | -27.17% |
| Diluted EPS (TTM) | -2.77 |
| Quarterly Revenue Growth (YOY) | 28.10% |
| Total Debt/Equity (MRQ) | 13.81% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | -61.32 M |
| Levered Free Cash Flow (TTM) | -19.29 M |
| Return on Assets (TTM) | -7.06% |
| Return on Equity (TTM) | -23.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Glaukos Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.10 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.30% |
| % Held by Institutions | 102.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 175.00 (Mizuho, 88.14%) | Buy |
| Median | 115.00 (23.63%) | |
| Low | 72.00 (Morgan Stanley, -22.60%) | Sell |
| Average | 122.25 (31.43%) | |
| Total | 6 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 86.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 06 May 2025 | 72.00 (-22.59%) | Sell | 87.20 |
| Stephens & Co. | 02 May 2025 | 115.00 (23.63%) | Buy | 87.61 |
| Needham | 01 May 2025 | 115.00 (23.63%) | Buy | 83.54 |
| Stifel | 01 May 2025 | 115.00 (23.63%) | Buy | 83.54 |
| Truist Securities | 01 May 2025 | 135.00 (45.13%) | Buy | 83.54 |
| 11 Apr 2025 | 140.00 (50.51%) | Buy | 90.07 | |
| Wells Fargo | 01 May 2025 | 86.00 (-7.54%) | Hold | 83.54 |
| Mizuho | 16 Apr 2025 | 175.00 (88.14%) | Buy | 88.80 |
| Piper Sandler | 15 Apr 2025 | 165.00 (77.39%) | Buy | 94.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | Glaukos Announces Participation in Upcoming Investor Conferences |
| 30 Apr 2025 | Announcement | Glaukos Announces First Quarter 2025 Financial Results |
| 23 Apr 2025 | Announcement | Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting |
| 16 Apr 2025 | Announcement | Glaukos Announces the Release of its 2024 Sustainability Report |
| 09 Apr 2025 | Announcement | Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 |
| 11 Mar 2025 | Announcement | RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |